Apraglutide's 2025 Launch Will Expand Market Presence

Published
17 Sep 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
US$0.95
33.7% overvalued intrinsic discount
07 Aug
US$1.27
Loading
1Y
-74.8%
7D
12.4%

Author's Valuation

US$0.9

33.7% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 68%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 61%

AnalystConsensusTarget has decreased revenue growth from 5.8% to 2.6%, increased profit margin from 2.9% to 17.3% and decreased future PE multiple from 169.1x to 11.9x.

Shared on09 Apr 25

AnalystConsensusTarget has increased discount rate from 10.2% to 11.3%.

Shared on02 Apr 25
Fair value Decreased 4.65%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 4.22%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 799%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25